Effimune

What Effimune does

Effimune, operating through OSE Immunotherapeutics, is a clinical-stage biotechnology company founded in 2007 and headquartered in Nantes, France, with additional offices in Paris. The company researches and develops drugs for transplantation and immune-mediated diseases, focusing on first-in-class immunotherapies in Immuno-Oncology and Immuno-Inflammation. Its pipeline comprises seven candidates spanning therapeutic cancer vaccines (Tedopi, OSE-279), immune-regulation antibodies (Lusvertikimab/OSE-127, Pegrizeprument/FR104), partnered assets (BI 770371 with Boehringer Ingelheim; ABBV-230 with AbbVie), and a preclinical myeloid checkpoint program (CLEC-1).

The underlying science rests on three patented research platforms: (1) a neoepitope-based platform that activates cytotoxic T cells for cancer indications, (2) a tumor-microenvironment platform that converts suppressive cells into effector cells, and (3) an immune-regulation platform that downregulates effector T cells and upregulates regulatory T cells for autoimmune and inflammatory conditions. The lead program, Tedopi, is in a Phase 3 pivotal trial (ARTEMIA) in non-small cell lung cancer, and has received two positive Independent Data Monitoring Committee reviews as of February 2026.

The business model is pre-commercial: the company generates no product revenue today, relying instead on capital markets (it is listed on Euronext Paris under ticker OSE) and pharmaceutical partnerships for development funding. Future commercialization would occur through partner-led distribution channels following regulatory approval, targeting oncology and immunology patients via healthcare providers. The organization is small (11-50 employees) and R&D-intensive, with leadership including a Chief Development and Regulatory Officer overseeing clinical and regulatory execution.

Name

Effimune

Legal name

OSE Immunotherapeutics

Website

https://effimune.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Effimune, operating as OSE Immunotherapeutics, is a Nantes-based clinical-stage biotechnology company developing first-in-class immunotherapies for cancer and immune-mediated diseases through three patented research platforms and a seven-asset pipeline led by a Phase 3 therapeutic cancer vaccine for non-small cell lung cancer.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy Drugs

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Transplant & Immunosuppression Specialty Pharmaceuticals (HLAIACAJ), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

Keywords

• Cancer immunotherapy drugs
• Therapeutic cancer vaccines
• Immune modulation therapies
• Clinical stage biotech
• Immuno-oncology treatments

Headquarters

HQ city

Nantes

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Marketing channels4 records

Core offering

Effimune is a biotechnology company that conducts research and development of drugs for transplantation and immune-mediated diseases. Its pipeline spans immuno-oncology (including therapeutic cancer vaccines for non-small cell lung cancer) and immuno-inflammation (antibody-based therapies), supported by three proprietary patented research platforms. The company operates as a clinical-stage developer, advancing first-in-class immunotherapy candidates both independently and through pharmaceutical partnerships.

Product overview

OSE Immunotherapeutics is a clinical-stage biotechnology company developing a portfolio of first-in-class immunotherapies for Immuno-Oncology and Immuno-Inflammation. The company's product portfolio includes seven distinct therapeutic candidates: Tedopi® (a therapeutic cancer vaccine in Phase 3 for non-small cell lung cancer), OSE-279, Lusvertikimab (OSE-127), Pegrizeprument (FR104), BI 770371, ABBV-230, and CLEC-1. These products are developed through three proprietary preclinical research platforms focused on delivering next-generation immunotherapy treatments through activation of cytotoxic T cells, transformation of suppressive tumor microenvironment cells, and regulation of immune responses.

Differentiator

Problem solved

Functional benefit

Brands

• Tedopi®: Therapeutic cancer vaccine in Phase 3 clinical trial (ARTEMIA) for non-small cell lung cancer
• OSE-279
• Lusvertikimab (OSE-127)
• Pegrizeprument (FR104)
• BI 770371
• ABBV-230
• CLEC-1

Products and services

• Tedopi®

Quantifiable outcome

• Second positive IDMC review for Phase 3 ARTEMIA trial of Tedopi in NSCLC

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Recent moves4 records

Expansion highlights4 records

Market position

Competitive moat4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/effimune

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Effimune